Searle Celebrex APC Trial Could Be Sufficient For SAP Indication – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Searle’s recently initiated Adenoma Prevention with Celecoxib (APC) study could be adequate to support a Celebrex indication for spontaneous adenomatous polyposis (SAP), FDA said in review documents for the drug’s familial adenomatous polyposis (FAP) indication.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class